Outlook Therapeutics, Inc.
OTLK
$2.41
-$0.295-10.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.15M | -46.36M | 17.38M | 5.69M | 44.41M |
| Total Depreciation and Amortization | 29.40K | 29.10K | 28.80K | 28.80K | 28.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.04M | 35.67M | -35.26M | -26.92M | -62.17M |
| Change in Net Operating Assets | 2.19M | -5.92M | 6.89M | 4.22M | -1.78M |
| Cash from Operations | -11.90M | -16.58M | -10.97M | -16.98M | -19.51M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 0.00 | 33.10M | -- | -- | -- |
| Total Debt Repaid | -907.00K | -32.91M | -- | 0.00 | 0.00 |
| Issuance of Common Stock | 14.15M | 18.25M | 1.74M | -- | 4.31M |
| Repurchase of Common Stock | -- | -- | -- | -115.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13.25M | 18.44M | 1.74M | -115.00K | 4.31M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.34M | 1.85M | -9.23M | -17.10M | -15.20M |